JNCIJClub
Cross-ancestry proteome-wide mendelian randomization of plasma proteins and breast cancer susceptibility.
JNCI: Journal of the National Cancer Institute · · Journal Article · Open access
Wu, Godbole + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Cross-ancestry proteome-wide Mendelian randomization identifies 12 plasma proteins linked to breast cancer susceptibility, with Bonferroni significance (P < 0.05/1,971 tests) across ancestries.
- Why it matters: The plasma proteome could translate inherited breast cancer risk into interpretable targets, but proteome-wide Mendelian randomization evidence across multiple ancestries has been limited.
- What they did: Using cis-protein quantitative trait loci for 1,962 proteins from 34,557 European-ancestry UK Biobank Pharma Proteomics participants, the study tested breast cancer risk in 156,901 cases and 204,634 controls across European, East Asian, and African ancestries. Ancestry-specific MR estimates were combined via fixed-effects meta-analysis, then candidates were assessed with subtype-specific and reverse-direction MR, colocalization (PPH4 ≥ 0.80), and replication in independent proteomic datasets plus protein polygenic score analyses in All of Us.
- The result: Twelve proteins met the cross-ancestry threshold, with heterogeneity noted for DNPH1 and cross-subtype heterogeneity for CASP8, RALB, and USP28; multiple candidates showed colocalization, replication, and consistent direction, with strongest cumulative support for LRRC25, PARK7, and LRRC37A2.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- Open access
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.